期刊文献+

单克隆IgM相关轻链型淀粉样变的临床特征和预后分析

Clinical characteristics and prognostic analysis of monoclo- nal IgM-related AL amyloidosis
收藏 分享 导出
摘要 在轻链型(AL型)淀粉样变中,最常见的单克隆免疫球蛋白(M蛋白)类型为IgG和IgA型,IgM和IgD型相对少见。既往文献显示,IgM-AL型淀粉样变仅占所有AL型淀粉样变的不足10%,且IgM-AL型淀粉样变起病更晚,淋巴结受累更多见。本研究回顾性分析我院确诊的IgM-AL型淀粉样变患者的临床、实验室检查特征、治疗及生存数据,以提高对此类疾病的认识。
作者 毛玥莹 冯俊 孟琦 沈恺妮 曹欣欣 周道斌 李剑 Mao Yueying, Feng Jun, Meng Qi, Shen Kaini, Cao Xinxin, Zhou Daobin, Li Jian(Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China)
出处 《中华血液学杂志》 CSCD 北大核心 2017年第11期989-992,共4页 Chinese Journal of Hematology
作者简介 通信作者:李剑,Email:lijian@pumch.cn
  • 相关文献

参考文献2

二级参考文献38

  • 1Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? [J]. Blood Rev, 2012, 26 (4): 137- 154. doi: 10.1016/j.blre. 2012.03.001. 被引量:1
  • 2Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac tropo- nins and N-terminal pro-brain natriuretic peptide: a staging sys- tem for primary systemic amyloidosis [J].. J Clin Oncol, 2004, 22 ( 18): 3751-3757. 被引量:1
  • 3Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements [J]. J Clin Oncol, 2012, 30(9): 989-995. doi: 10.1200/JCO.2011.38,5724. 被引量:1
  • 4Gillmore JD, Wechalekar A, Bird J, et al. Guidelines on the diag- nosis and investigation of AL amyloidosis [ J]. Br J Haematol, 2015, 168(2): 186-206. doi: 10.1111/bjh.13156. 被引量:1
  • 5Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment [J]. Am J Hematol, 2014, 89( 12): 1132-1140. doi: 10.1002/ajh.23828. 被引量:1
  • 6Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis [J]. Br J Haematol, 2015, 168 (2): 186-206. doi: 10.1111/bjh.13155. 被引量:1
  • 7Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage Ill AL amyloidosis [J]. Blood, 2013, 121 (17): 3420-3427. doi: 10.1182/blood-2012-12-473066. 被引量:1
  • 8Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders [J]. Leukemia, 2009, 23 (2): 215-224. doi: 10.1038/leu.2008.307. 被引量:1
  • 9Dispenzieri A, Buadi F, Kumar SK, et al. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement [J]. Mayo Clin Proc, 2015, 90 (8): 1054-1081. doi: 10.1016/j .mayocp.2015.06.009. 被引量:1
  • 10Weber N, Mollee P, Augustson B, et al. Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group [J]. InternMed J, 2015, 45 ( 41:371-382. doi: 10.1111/imj. 12566. 被引量:1

共引文献14

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈